Tvardi is conducting clinical trials with TTI-101 and TTI-109, oral drugs that inhibit STAT3, a protein that plays a key role in cancer and fibrosis.

In cancer, STAT3 can lead to tumor growth and metastasis, as well as limit the body’s ability to mount an immune response against cancer cells.

In fibrotic conditions, STAT3 plays a key role in fibrosis and limits the body’s ability to repair damaged cells.